Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343597 · ClinicalTrials.gov registry record
Volume Outcome Relationships and Effects
A clinical trial of Esophageal Cancer, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06343597: Recruiting study of Esophageal Cancer, sponsored by Methodist Health System.
NCT06343597 is a study of Esophageal Cancer that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 30 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06343597, a study of Esophageal Cancer, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
Primary Outcome
Retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with Esophageal Cancer than low-volume facilities
Conditions Studied
Study Locations (1)
Texas
- Methodist Richardson Medical Center - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2028-06-15 |
What NCT06343597 shows while recruiting
NCT06343597 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06343597 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06343597 about?
NCT06343597 is a clinical study titled "Volume Outcome Relationships and Effects". This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
What is the current status of trial NCT06343597?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2020-06-15. Estimated completion is 2028-06-15.
What conditions does trial NCT06343597 study?
This clinical trial studies the following conditions: Esophageal Cancer.
Who is sponsoring clinical trial NCT06343597?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343597 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06343597's enrollment target sits among peer trials
30 98th of 123 higher than 24 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI